HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,309,421 | +5.7% | 426,940 | -0.2% | 0.01% | +10.0% |
| Q2 2023 | $15,436,914 | -5.6% | 427,971 | -0.0% | 0.01% | -9.1% |
| Q1 2023 | $16,346,825 | -55.4% | 428,064 | -33.5% | 0.01% | -57.7% |
| Q4 2022 | $36,651,336 | +34.3% | 644,142 | -53.3% | 0.03% | +30.0% |
| Q3 2022 | $27,292,265 | -9.8% | 1,379,072 | +100.4% | 0.02% | -4.8% |
| Q2 2022 | $30,274,000 | +4.0% | 688,040 | -5.7% | 0.02% | +50.0% |
| Q1 2022 | $29,103,000 | +7.8% | 729,775 | +8.7% | 0.01% | +27.3% |
| Q4 2021 | $27,004,000 | +0.8% | 671,571 | +2.0% | 0.01% | -8.3% |
| Q3 2021 | $26,784,000 | -9.5% | 658,395 | +1.0% | 0.01% | -7.7% |
| Q2 2021 | $29,601,000 | +3.9% | 651,856 | -4.6% | 0.01% | 0.0% |
| Q1 2021 | $28,481,000 | -16.6% | 683,169 | -14.5% | 0.01% | -18.8% |
| Q4 2020 | $34,143,000 | +46.1% | 799,410 | -10.1% | 0.02% | +33.3% |
| Q3 2020 | $23,371,000 | – | 889,303 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |